PR95030

NEW YORK, March 17, 2022 /PRNewswire=KYODO JBN/ --

Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to

the development of transformational therapeutics and technologies for

neurological and psychiatric diseases, has entered into an agreement with

Columbia University ("Columbia") and the Research Foundation for Mental Hygiene

("RFMH"), to obtain worldwide exclusive rights to develop and commercialize

Columbia's proprietary CNS biomarker software platform and patent portfolio.

Logo - https://mma.prnewswire.com/media/1758607/terran_biosciences_Logo.jpg

The foundational algorithms were initially developed by a team of Columbia

physicians, neuroscientists, and software engineers, led by Guillermo Horga,

MD, PhD, and Clifford Cassidy, PhD. This novel technology has already

demonstrated promising clinical applications in several studies across a number

of indications including schizophrenia, Parkinson's disease, Alzheimer's

disease, major depression, drug addiction, and post-traumatic stress disorder

(PTSD).

On the back of this data, Terran is further developing the algorithms by

incorporating them into Terran's cloud-based software as a medical device

(SaMD) platform. Terran is also sponsoring additional clinical research studies

at RFMH and Columbia, and is expanding the dataset, indications of interest,

and patent portfolio. Terran aims to bring forward this platform to help enable

non-invasive and cost-effective solutions for patients suffering from

neurological and psychiatric disorders.

Dr. Sam Clark, Terran's CEO, commented "The team at Columbia and RFMH has done

an incredible amount of work in building out this software platform to help

solve very difficult questions around the identification and measurement of key

brain biomarkers in neuropsychiatry. We are looking forward to continuing this

research collaboration to further this work and broaden the access to this

powerful technology."

Dr. Guillermo Horga, Associate Professor of Clinical Psychiatry at Columbia

University Vagelos College of Physicians and Surgeons, stated, "We are excited

to continue the collaboration with the Terran team to push this work even

further and explore its capabilities across a number of different disease

states and applications."

About Terran Biosciences, Inc.

Terran is a biotech platform company developing a portfolio of therapeutics and

technologies for patients with neurological and psychiatric diseases. Backed by

a number of life-science and tech investors, Terran has built a CNS-focused,

tech-enabled drug development platform, and is rapidly advancing of number of

late-stage assets, which include novel psychedelic-based therapeutics.

Terran Contact

Investor Relations:

ir@terranbiosciences.com

Media:

info@terranbiosciences.com

SOURCE  Terran Biosciences, Inc.